Company Overview
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, and aesthetics. This operational focus places the firm squarely within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, positioning it as a provider of essential therapeutic solutions and consumer health items. The company demonstrates a significant operational scale with a total market capitalization of $1.86B, annual revenue of $10.27B, and an employee base of 20,300 individuals. These valuation and revenue figures indicate that Bausch Health is a large-cap entity within its specific niche, leveraging a substantial workforce to generate multi-billion dollar sales while maintaining a market valuation that reflects its specialized product portfolio rather than broad-market dominance.
Financial Health
The company reports a trailing twelve-month revenue of $10.27B, with a corresponding net income of $157.00M and EBITDA of $3.40B. The substantial disparity between the $10.27B revenue and the $157.00M net income reveals a cost structure where operating expenses and taxes consume the vast majority of gross proceeds, leaving a profit margin of only 1.5%. Despite this thin bottom line, the entity generates robust free cash flow of $1.09B, which provides significant financial flexibility for operational expenditures, debt servicing, or potential strategic initiatives without relying on external financing. Profitability analysis shows a gross margin of 70.7%, indicating strong pricing power or cost advantages in manufacturing, while the operating margin stands at 25.8% and the final profit margin remains at 1.5%. The balance sheet presents a highly leveraged profile with total debt of $21.08B compared to liquid cash of $1.31B, resulting in a debt-to-equity ratio of 5591.25%. Short-term liquidity is supported by a current ratio of 1.47, suggesting the company holds sufficient current assets to cover its current liabilities with a modest buffer. Return on Equity reaches 436.4% and Return on Assets sits at 5.2%, metrics that reflect the mathematical impact of the company's high leverage on equity returns rather than necessarily indicating superior operational efficiency in asset utilization.
Valuation Assessment
Valuation metrics for Bausch Health Companies Inc. show a P/E Ratio (TTM) of 11.93 and a Forward P/E of 1.25. The drastic difference between these two ratios implies that the market anticipates a massive expansion in future earnings that would otherwise result in an extremely low multiple, or that the current earnings base is exceptionally high relative to future expectations. The price-to-book ratio is listed at -3.35, a negative figure that indicates the market capitalization is below the company's book value, often seen in capital-intensive or distressed scenarios where asset revaluation is expected. Alternative valuation measures include a price-to-sales ratio of 0.18 and an EV/EBITDA of 6.63, suggesting the stock trades at a fraction of its sales revenue and at a low multiple of earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. Price action over the last year ranges between a 52-week high of $8.69 and a 52-week low of $4.25, meaning the current market price sits significantly below the recent peak and within the lower half of the observed trading range. The stock exhibits a beta of 0.37, which indicates that its price volatility is substantially lower than that of the broader market, suggesting it moves with less intensity than large-cap peers during periods of market fluctuation.
Growth & Income
Revenue growth for the trailing twelve months stands at 9.3%, while earnings growth is not applicable or N/A based on available data. The absence of reported earnings growth figures relative to the positive revenue growth implies that top-line expansion is not yet translating into proportional bottom-line improvements, likely due to the high fixed cost structure inherent in the pharmaceutical and medical device industries. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status indicates that the company retains all of its earnings rather than distributing them to shareholders, a strategy often adopted by firms with high debt loads or those prioritizing capital allocation toward debt reduction and organic growth initiatives. Consequently, the overall growth and income profile is characterized by moderate revenue expansion in a specialized sector, coupled with a capital retention strategy that offers no current income yield to investors.